Initial treatment¹

To start a new patient on Versacloz:

1. Order Baseline Labs:
   • Prior to initiating treatment, obtain a baseline absolute neutrophil count (ANC)
   • For patients with documented Benign Ethnic Neutropenia (BEN), obtain at least two baseline ANC levels
2. Verify Lab Results:
   • General Population: VERSACLOZ initiation is not recommended in patients with a baseline ANC less than 1500/µL
   • Patients with BEN: VERSACLOZ initiation is not recommended in patients with BEN with a baseline ANC less than 1000/µL
3. Write prescription

Important Safety Information

DRUG INTERACTIONS

• CYP1A2 Inhibitors: Reduce VERSACLOZ dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin). Dose reduction may be necessary with concomitant use of moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives or caffeine).
• CYP2D6 or CYP3A4 Inhibitors. Dose reduction may be necessary with concomitant use of CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline).
• CYP1A2 or CYP3A4 Inducers. Concomitant use with strong CYP3A4 inducers (carbamazepine, phenytoin, St. John's wort, rifampin) is not recommended. Dose increase may be necessary with concomitant use of moderate CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers. Consider reducing VERSACLOZ dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 (e.g., carbamazepine) inducers are discontinued.

Please see the full Prescribing Information for Important Safety Information, including
BOXED Warning.

Click here for additional safety information.

Reference: 1. Versacloz^® Prescribing Information, Douglas Pharmaceuticals America Ltd. 2025